Leukemia Research
Volume 33, Issue 12 , Pages 1604-1608 , December 2009

Long-term survival in chronic myelocytic leukemia after a first primary malignancy

  • Hermann Brenner

      Affiliations

    • Division of Clinical Epidemiology and Aging Research, German Cancer Research Center, Bergheimer Str. 20, D-69115 Heidelberg, Germany
    • Corresponding Author InformationCorresponding author. Tel.: +49 6221 548140; fax: +49 6221 548142.
    • ,
  • Adam Gondos

      Affiliations

    • Division of Clinical Epidemiology and Aging Research, German Cancer Research Center, Bergheimer Str. 20, D-69115 Heidelberg, Germany
    • ,
  • Dianne Pulte

      Affiliations

    • Division of Clinical Epidemiology and Aging Research, German Cancer Research Center, Bergheimer Str. 20, D-69115 Heidelberg, Germany
    • Weill Cornell Medical Center, New York, USA

Received 26 December 2008 ,Revised 27 January 2009 ,Accepted 28 January 2009.

References 

  1. Aguiar RC. Therapy-related chronic myeloid leukemia: an epidemiological, clinical and pathogenetic appraisal. Leuk Lymphoma. 1998;29:17–26
  2. Nandakumar A, Davis S, Moolgavkar S, Witherspoon RP, Schwartz SM. Myeloid leukaemia following therapy for a first primary cancer. Br J Cancer. 1991;63:782–788
  3. Howard RA, Gilbert ES, Chen BE, Hall P, Storm H, Pukkala E, et al. Leukemia following breast cancer: an international population-based study of 376,825 women. Breast Cancer Res Treat. 2007;105:359–368
  4. Shimon I, Kneller A, Olchovsky D. Chronic myeloid leukaemia following 131I treatment for thyroid carcinoma: a report of two cases and review of the literature. Clin Endocrinol (Oxf). 1995;43:651–654
  5. Moloney WC. Radiogenic leukemia revisited. Blood. 1987;70:905–908
  6. Larson RA. Is secondary leukemia an independent poor prognostic factor in acute myeloid leukemia?. Best Pract Res Clin Haematol. 2007;20:29–37
  7. Cohen MH, Williams G, Johnson JR, Duan J, Gobburu J, Rahman A, et al. Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia. Clin Cancer Res. 2002;8:935–942
  8. Druker BJ, Guilhot F, O’Brien SG, Gathmann I, Kantarjian H, Gattermann N, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 2006;355:2408–2417
  9. Kantarjian H, Sawyers C, Hochhaus A, Guilhot F, Schiffer C, Gambacorti-Passerini C, et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med. 2002;346:645–652
  10. Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) Limited-Use Data (1973–2004), National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released April 2007, based on the November 2006 submission.
  11. Brenner H, Gefeller O, Hakulinen T. Period analysis for ‘up-to-date’ cancer survival data: theory, empirical evaluation, computational realisation and applications. Eur J Cancer. 2004;40:326–335
  12. Brenner H, Hakulinen T. Up-to-date and precise estimates of cancer patient survival: model-based period analysis. Am J Epidemiol. 2006;164:689–696
  13. Brenner H, Gefeller O. An alternative approach to monitoring cancer patient survival. Cancer. 1996;78:2004–2010
  14. Brenner H, Hakulinen T. Up-to-date long-term survival curves of patients with cancer by period analysis. J Clin Oncol. 2002;20:826–832
  15. Brenner H, Soderman B, Hakulinen T. Use of period analysis for providing more up-to-date estimates of long-term survival rates: empirical evaluation among 370,000 cancer patients in Finland. Int J Epidemiol. 2002;31:456–462
  16. Ederer F, Axtell LM, Cutler SJ. The relative survival rate: a statistical methodology. Natl Cancer Inst Monogr. 1961;6:101–121
  17. Henson DE, Ries LA. The relative survival rate. Cancer. 1995;76:1687–1688
  18. Ederer F, Heise H. Instructions to IBM 650 programmers in processing survival computations. Methodological note No. 10. Bethesda, MD: National Cancer Institute; 1959.
  19. Arias E. United States life tables, 2000. vol. 51: Natl Vit Stat Rep;2002:1–39.
  20. Guilhot F, Apperley J, Kim DW, Bullorsky EO, Baccarini M, Roboz GJ, et al. Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase. Blood. 2007;109:4143–4150
  21. Kantarjian H, Talpaz M, O’Brien S, Giles F, Faderl S, Verstovsek S, et al. Survival benefit with imatinib mesylate therapy in patients with accelerated-phase chronic myelogenous leukaemia—comparison with historic experience. Cancer. 2005;103:2099–2108
  22. Kantarjian HM, Cortes JE, O’Brien S, Luthra R, Giles F, Verstovsek S, et al. Long-term survival benefit and improved complete cytogenetic and molecular response rates with imatinib mesylate in Philadelphia chromosome-positive chronic-phase chronic myeloid leukemia after failure of interferon-alpha. Blood. 2004;104:1979–1988
  23. Kantarjian HM, Talpaz M, O’Brien S, Jones D, Giles F, Garcia-Manero G, et al. Survival benefit with imatinib mesylate versus interferon-alpha-based regimens in newly diagnosed chronic-phase chronic myelogenous leukemia. Blood. 2006;108:1835–1840
  24. Ramanarayanan J, Dunford LM, Baer MR, Sait SN, Lawrence W, McCarthy PL. Chronic myeloid leukemia after treatment of lymphoid malignancies: response to imatinib mesylate and favorable outcomes in three patients. Leuk Res. 2006;30:701–705
  25. Nilsson B, Sjolund K, Kindblom LG, Meis-Kindblom JM, Bumming P, Nilsson O, et al. Adjuvant imatinib treatment improves recurrence-free survival in patients with high-risk gastrointestinal stromal tumours (GIST). Br J Cancer. 2007;96:1656–1658
  26. Bajaj GK, Zhang Z, Garrett-Mayer E, Drew R, Sinibaldi V, Pili R, et al. Phase II study of imatinib mesylate in patients with prostate cancer with evidence of biochemical relapse after definitive radical retropubic prostatectomy or radiotherapy. Urology. 2007;69:526–531
  27. Lin AM, Rini BI, Weinberg V, Fong K, Ryan CJ, Rosenberg JE, et al. A phase II trial of imatinib mesylate in patients with biochemical relapse of prostate cancer after definitive local therapy. BJU Int. 2006;98:763–769
  28. Modi S, Seidman AD, Dickler M, Moasser M, D’Andrea G, Moynahan ME, et al. A phase II trial of imatinib mesylate monotherapy in patients with metastatic breast cancer. Breast Cancer Res Treat. 2005;90:157–163
  29. Rocha A, Azevedo I, Soares R. Progesterone sensitizes breast cancer MCF7 cells to imatinib inhibitory effects. J Cell Biochem. 2008;103:607–614
  30. Taja-Chayeb L, Chavez-Blanco A, Martinez-Tlahuel J, Gonzales-Fierro A, Candelaria M, et al. Expression of platelet derived growth factor family members and the potential role of imatinib mesylate for cervical cancer. Cancer Cell Int. 2006;6:22
  31. Itsukuma T, Ishikawa H, Misawa M, Fujimori Y, Nakagawa K, Hirota S, et al. Familial adenomatous polyposis complicated by chronic myelogenous leukemia: response to imatinib mesylate. J Gastroenterol. 2007;42:402–405

PII: S0145-2126(09)00057-5

doi: 10.1016/j.leukres.2009.01.042

Leukemia Research
Volume 33, Issue 12 , Pages 1604-1608 , December 2009

Article Tools

* Image Usage & Resolution